Close

Human EGFRVIII CAR Detection Reagent, His Tag (CARD-LX056)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Evaluating CAR expression is an essential step in the production of CAR-T cells. Creative biolabs provides several detection reagents which are uniquely suitable for evaluation of CAR expression. Human EGFRVIII CAR Detection Reagent, His Tag is a special detection reagent which carries a polyhistidine tag at the C-terminus, and is used to detect human EGFRVIII CAR related to the study of Glioblastoma.

Specific Inquiry

  • Size:
  • Form:
  Add to Cart

Specifications

  • Target
  • EGFRVIII
  • Application
  • ELISA, FC
  • Purity
  • >90%
  • Endotoxin Level
  • Less than 1.0 EU per μg by the LAL method.
  • Storage
  • For long term storage, the product should be stored at lyophilized state at -66°C or lower.
    Please avoid repeated freeze-thaw cycles.
  • Application Notes
  • The optimal working dilutions should be determined by the end user.
  • Diseases
  • Glioblastoma
  • Molecular Characterization
  • It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
  • Conjugation
  • Unconjugated
  • Tag
  • His Tag
  • Size
  • 1 mg
  • Formulation
  • Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
  • Expression
  • Human HEK293 cells
  • Host Species
  • Human
  • Species Reactivity
  • Human
  • Form
  • Lyophilized
  • Images
  • Figure 1 Structure

Target

  • Target Introduction
  • The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. The type III EGF deletion-mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors; EGFR gene amplification is correlated with the structural rearrangement of the gene. The EGFRvIII gene has an in-frame deletion of 801 base pairs, corresponding to exons 2-7 in the mRNA, resulting in the deletion of amino acids 30-297 in the extracellular domain and the generation of a glycine at the fusion point.
  • Target Alternative Names
  • epidermal growth factor receptor

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human EGFRVIII CAR Detection Reagent, His Tag (CARD-LX056). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.